Clinical Research Papers:
Development and validation of a prognostic nomogram based on the log odds of positive lymph nodes (LODDS) for breast cancer
Metrics: PDF 2244 views | HTML 2344 views | ?
Jiahuai Wen1,*, Feng Ye1,*, Xiaofang He1, Shuaijie Li1, Xiaojia Huang1, Xiangsheng Xiao1 and Xiaoming Xie1
1 Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China
* These authors have contributed equally to this work
Xiaoming Xie, email:
Keywords: breast cancer, LODDS, prognosis, nomogram, surgery
Received: November 23, 2015 Accepted: February 24, 2016 Published: March 15, 2016
Background: To evaluate the prognostic effect of log odds of positive lymph nodes (LODDS) and develop a nomogram for survival prediction in breast cancer patients at the time of surgery.
Results: LODDS was an independent risk factor for cancer-related death in breast cancer (hazard ratio: 1.582, 95%CI: 1.190-2.104). Menopausal status, tumor size, pathological lymph node staging, estrogen receptor status and human epidermal growth factor receptor-2 status were also included in the nomogram. The calibration plots indicated optimal agreement between the nomogram prediction and actual observation. Discrimination of nomogram was superior to the seventh edition TNM staging system [C-index: 0.745 vs. 0.721 (p = 0.03) in training cohort; 0.796 vs. 0.726 (p < 0.01) in validation cohort].
Methods: We retrospectively evaluated 2023 breast cancer patients from Jan 2002 to Dec 2008 at our center. The cohort was randomly divided into training cohort and validation cohort. Univariate and multivariate analyses were performed to identify prognostic factors, and nomogram was established using Cox regression model in training cohort. External validation of the nomogram was performed in the validation cohort.
Conclusions: The LODDS is an independent prognostic indicator in breast cancer and the novel nomogram can provide individual prediction of cancer-specific survival and help prognostic assessment for breast cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.